Most side effects with the Wegovy Pill are temporary and improve as your body adjusts. Understanding what to expect and how to manage common symptoms can help you feel more confident throughout your treatment.
Like all medicines, the Wegovy Pill can cause side effects. The most common are digestive symptoms such as nausea, bloating, constipation and diarrhoea, particularly when you first start treatment or after your dose increases. For most people, these are mild to moderate and improve as the body adapts.¹ Knowing what is normal, what you can do to help and when to seek advice can make the early weeks feel much more manageable.
Just getting started?
Before diving into the science behind successful weight loss, download Your Guide to the Wegovy Pill. It covers everything you need to know about taking the medication, managing side effects, building healthy habits and getting the most from your treatment.
Why do side effects happen?
The Wegovy Pill works by slowing the rate at which food leaves your stomach, helping you feel fuller for longer and reducing appetite. These are the same effects that support weight loss, but they also explain why some people experience digestive symptoms in the early weeks.² As your digestive system adjusts to working differently, you may notice nausea, bloating, constipation or diarrhoea. Andre da Silva Lage, our Superintendent Pharmacist, shares what most people experience in the early weeks.
Everyone responds differently. Some people experience very few side effects, while others notice more as their body adapts. This is one of the reasons the dose increases gradually over twelve weeks, giving your body time to adjust at each stage before moving to the next.³
What the OASIS 4 trial showed
In the OASIS 4 trial, digestive side effects were the most commonly reported adverse events among people taking oral semaglutide 25 mg.¹ The most frequently reported were:
- Nausea: 46.6% of participants on oral semaglutide versus 18.6% on placebo
- Vomiting: 30.9% versus 5.9% on placebo
- Constipation: 20.1% of participants on oral semaglutide
- Diarrhoea: also commonly reported during treatment
These numbers are worth knowing and worth putting in context. The vast majority of side effects were mild to moderate and temporary, improving as participants continued treatment. Only 6.9% of participants permanently stopped treatment because of side effects.¹ Side effects are common, but they are usually manageable and often ease considerably as your body adjusts.
Common Side Effects and What May Help
| Side Effect | Self-Care Tips |
|---|---|
| Nausea | Eat slowly, choose smaller meals, avoid rich or greasy foods and stay hydrated. |
| Constipation | Increase fluids, include fibre-rich foods where tolerated and keep moving throughout the day. |
| Diarrhoea | Stay hydrated and choose simple, easy-to-digest foods until symptoms settle. |
| Indigestion or reflux | Avoid large meals, eat more slowly and avoid lying down immediately after eating. |
| Bloating | Smaller meals, regular movement and avoiding overeating may help. |
| Tiredness | Ensure adequate hydration, nutrition, sleep and recovery while your body adjusts to treatment. |
What to eat when side effects are at their worst
When nausea or digestive discomfort is at its most noticeable, typically in the first week of a new dose, what you eat can make a real practical difference. Clinical guidance specifically recommends bland, low-fat foods during periods of stomach upset.⁴
Foods that tend to be well tolerated include:
- Plain rice, oats or toast
- Bananas or soft fruit
- Broth-based soups
- Eggs, grilled chicken or white fish
- Plain Greek yoghurt or cottage cheese
These foods are easier for a slowing digestive system to process and are less likely to trigger or worsen nausea.⁴ They are not a permanent way of eating; they are a short-term strategy for the days when symptoms feel more disruptive.
As symptoms ease, the aim is to gradually return to a more balanced plate with lean protein, cooked vegetables, wholegrains and soft fruit. Your appetite and tolerance will guide that transition.
When to Speak to Your Clinical Team
Contact your clinical team if you experience:
- Persistent vomiting or diarrhoea preventing you from keeping food or fluids down
- Signs of dehydration such as dizziness, feeling faint or passing very little urine
- Severe or persistent abdominal pain
- Constipation that is not improving with dietary changes
- Side effects affecting your ability to take your medication or carry out daily activities
- Any symptoms that concern you or feel unusual
The clinical team can review your symptoms, advise on management and adjust your dose escalation schedule where needed. A slower titration has been shown to reduce side effects without compromising the effectiveness of treatment.³ You do not need to wait until symptoms become severe before reaching out.
If you experience severe or persistent abdominal pain, stop taking your weight loss treatment and seek urgent medical advice through NHS 111 or your GP.
You do not have to manage this alone
Side effects can feel disruptive, particularly in the first few weeks. But support is available throughout your treatment. Your Clinician is here to review your treatment and make adjustments where needed. You can reach your clinical team anytime through My Account. Your Health Coach can help with practical strategies around food choices and meal timing. Book a session with your Health Coach via My Account whenever you need support.
Log into My AccountReferences
- Wharton S, Lingvay I, Bogdanski P, et al; OASIS 4 Study Group. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969
- Gentinetta S, Buso R, Careddu G, et al. Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonists. Diabetes Metab Syndr Obes. 2024;17:4697–4707. doi:10.2147/DMSO.S494919
- Le Roux CW, et al. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. Front Endocrinol. 2026;17:1788698. doi:10.3389/fendo.2026.1788698
- Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. doi:10.3390/jcm12010145
- Lingvay I, Ramírez-Jiménez A, Bebe A, et al. GLP-1 and GIP receptor agonists: effects on the gastrointestinal tract and management strategies for primary care physicians. Mayo Clin Proc. 2025. doi:10.1016/j.mayocp.2025.07.009
- Barrea L, Annunziata G, Muscogiuri G, et al. Optimizing GLP-1 therapies for obesity and diabetes management. Nutrients. 2025. Available from: ncbi.nlm.nih.gov/pmc/articles/PMC12661421
